Tromsø, 25 September, 2011: Biotec Pharmacon ASA, via its subsidiary ArcticZymes AS, and Affymetrix Inc. have signed a new non-exclusive supply agreement for deliveries of ArcticZymes' top-selling enzyme Shrimp Alkaline Phosphatase (SAP).
Affymetrix has previously held an exclusive right to distribute SAP, whereas the new agreement enables ArcticZymes to offer SAP for sale also to other customers. At the same time the new agreement provides Affymetrix with a secure long term supply of SAP at competitive prices and non-exclusive rights to market, distribute and sell the product or combinations with other products for life science and diagnostic applications. The new agreement is effective from 23rd September, 2011 and initially runs through December 2017.
Sales of the SAP-enzyme are accounting for a majority of sales in ArcticZymes.
-Although we have broadened our enzyme portfolio with several new launches over the past few years, SAP remains our top-selling product. We are currently building our organization and increasing our sales and marketing capabilities, and it has been very important for us to gain control over the commercial development of our SAP enzyme, says Managing Director Jan Buch Andersen in ArcticZymes.
-The new agreement opens the possibility to address potentially large new market opportunities, at the same time allowing Affymetrix a secure long term supply of SAP on competitive terms. Hopefully, this will increase our sales and also make our revenue and earnings less volatile, says Buch Andersen.